Niagen Bioscience Inc (NAGE)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 59 | 67 | 72 | 84 | 100 | 129 | 129 | 134 |
| Operating profit | $m | 14 | 9 | ||||||
| Net profit | $m | -20 | -27 | -17 | -5 | 9 | 17 | 16 | 12 |
| EPS reported | $ | 0.20 | 0.19 | ||||||
| Operating cashflow per share | $ | 0.17 | 0.07 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | 0.17 | 0.07 | ||||||
| Free cash flow | $m | 13 | 6 | ||||||
| Net debt | $m | -64 | -67 | ||||||
| Book value equity | $m | 77 | 83 | ||||||
| Book value per share | $ | 0.90 | 1.00 | ||||||
| Number of shares | m | 85.44 | 82.5 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 31.80 | 15.99 | ||||||
| P/B LTM | x | 6.58 | 6.10 | ||||||
| P/S LTM | x | 3.89 | 3.90 | ||||||
| P/FCF LTM | x | 38.31 | 88.75 | ||||||
| EV/EBITDA LTM | x | 22.48 | 23.90 | ||||||
| EV/Sales LTM | x | 3.41 | 1.36 | ||||||
| Earnings Yield LTM | % | +3.14% | +6.25% | ||||||
| FCF Yield | % | +2.61% | +1.13% | ||||||
| Quality | |||||||||
| ROE | % | +22.71% | +20.50% | ||||||
| ROIC | % | +15.61% | +8.75% | ||||||
| Operating margin | % | +11.05% | +6.67% | ||||||
| Gross margin | % | +64.28% | +64.24% | ||||||
| FCF/Sales | % | +10.16% | +4.40% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +81.82% | +72.73% | ||||||
| Sales Growth YoY | % | +29.95% | +29.61% | ||||||
| Net Income Growth YoY | % | +103.30% | +87.03% | ||||||
| FCF Growth | % | +10.04% | -52.50% | ||||||
| Operating Profit Growth | % | +85.04% | +11.51% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 4.67 | 2.44 | ||||||
| Net Debt/EBITDA | x | -3.16 | -3.49 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | +0.20% | 0.00% | ||||||
| Net debt/Equity | x | -0.83 | -0.81 | ||||||
| Gross debt/equity | x | 0.04 | 0.03 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free